TAGRISSO Demonstrated Strong Overall Survival Benefit In The ADAURA Phase III Trial For Adjuvant Treatment Of Patients With Early-Stage EGFR-Mutated Lung Cancer
March 10, 2023
March 10, 2023
WILMINGTON, Delaware, March 10 -- AstraZeneca, a biopharmaceutical company, issued the following news release on March 9, 2023:
Positive high-level results from the ADAURA Phase III trial showed AstraZeneca's TAGRISSO (osimertinib) demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS), a key secondary endpoint, compared to placebo in the adjuvant treatment of patients with early-stage (IB, II and IIIA) epidermal growth factor recepto . . .
Positive high-level results from the ADAURA Phase III trial showed AstraZeneca's TAGRISSO (osimertinib) demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS), a key secondary endpoint, compared to placebo in the adjuvant treatment of patients with early-stage (IB, II and IIIA) epidermal growth factor recepto . . .